These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 37970598)
1. Mortality reduction in severe community-acquired pneumonia: key findings from a large randomized controlled trial and their clinical implications. Vornicu O; Perriens E; Blackman S; Smoos E; Al Sammour C; Oueslati I; Philippot A; Bankier DV; Haddad C; Bendoumou M; François T; Michaux I; Dincq AS; Evrard P; Bulpa P; Honore PM Ann Transl Med; 2023 Oct; 11(11):395. PubMed ID: 37970598 [No Abstract] [Full Text] [Related]
2. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Confalonieri M; Urbino R; Potena A; Piattella M; Parigi P; Puccio G; Della Porta R; Giorgio C; Blasi F; Umberger R; Meduri GU Am J Respir Crit Care Med; 2005 Feb; 171(3):242-8. PubMed ID: 15557131 [TBL] [Abstract][Full Text] [Related]
3. The effectiveness of the sarcopenia index in predicting septic shock and death in elderly patients with community-acquired pneumonia. Huang S; Zhao L; Liu Z; Li Y; Wang X; Li J; Chen X BMC Geriatr; 2022 Apr; 22(1):341. PubMed ID: 35439963 [TBL] [Abstract][Full Text] [Related]
4. Impact of Lymphocyte and Neutrophil Counts on Mortality Risk in Severe Community-Acquired Pneumonia with or without Septic Shock. Güell E; Martín-Fernandez M; De la Torre MC; Palomera E; Serra M; Martinez R; Solsona M; Miró G; Vallès J; Fernández S; Cortés E; Ferrer V; Morales M; Yébenes JC; Almirall J; Bermejo-Martin JF J Clin Med; 2019 May; 8(5):. PubMed ID: 31137863 [TBL] [Abstract][Full Text] [Related]
5. Validation of IDSA/ATS Guidelines for ICU Admission in Adults Over 80 Years Old With Community-Acquired Pneumonia. Cilloniz C; Ferrer M; Pericàs JM; Serrano L; Méndez R; Gabarrús A; Peroni HJ; Ruiz LA; Menéndez R; Zalacain R; Torres A Arch Bronconeumol; 2023 Jan; 59(1):19-26. PubMed ID: 36184303 [TBL] [Abstract][Full Text] [Related]
6. Effect of Hydrocortisone on Development of Shock Among Patients With Severe Sepsis: The HYPRESS Randomized Clinical Trial. Keh D; Trips E; Marx G; Wirtz SP; Abduljawwad E; Bercker S; Bogatsch H; Briegel J; Engel C; Gerlach H; Goldmann A; Kuhn SO; Hüter L; Meier-Hellmann A; Nierhaus A; Kluge S; Lehmke J; Loeffler M; Oppert M; Resener K; Schädler D; Schuerholz T; Simon P; Weiler N; Weyland A; Reinhart K; Brunkhorst FM; JAMA; 2016 Nov; 316(17):1775-1785. PubMed ID: 27695824 [TBL] [Abstract][Full Text] [Related]
7. Marked Reduction in 28-day Mortality Among Elderly Patients with Severe Community-acquired Pneumonia: Post Hoc Analysis of a Large Randomized Controlled Trial. Liu Y; Zhang C; Li C; Bai C; Shang H Clin Interv Aging; 2020; 15():2109-2115. PubMed ID: 33204076 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of glucocorticoids in the treatment of severe community-acquired pneumonia: A meta-analysis. Jiang S; Liu T; Hu Y; Li R; Di X; Jin X; Wang Y; Wang K Medicine (Baltimore); 2019 Jun; 98(26):e16239. PubMed ID: 31261585 [TBL] [Abstract][Full Text] [Related]
9. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Laterre PF; Garber G; Levy H; Wunderink R; Kinasewitz GT; Sollet JP; Maki DG; Bates B; Yan SC; Dhainaut JF; Crit Care Med; 2005 May; 33(5):952-61. PubMed ID: 15891319 [TBL] [Abstract][Full Text] [Related]
10. Community-acquired pneumonia in hospitalised patients: changes in aetiology, clinical presentation, and severity outcomes in a 10-year period. Sellarès-Nadal J; Burgos J; Martín-Gómez MT; Antón A; Sordé R; Romero-Herrero D; Bosch-Nicolau P; Falcó-Roget A; Kirkegaard C; Rodríguez-Pardo D; Len O; Falcó V Ann Med; 2022 Dec; 54(1):3052-3059. PubMed ID: 36331267 [TBL] [Abstract][Full Text] [Related]
11. Corticosteroids in Community-Acquired Pneumonia: A Review of Current Literature. Harris LK; Crannage AJ J Pharm Technol; 2021 Jun; 37(3):152-160. PubMed ID: 34752553 [No Abstract] [Full Text] [Related]
12. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. Torres A; Sibila O; Ferrer M; Polverino E; Menendez R; Mensa J; Gabarrús A; Sellarés J; Restrepo MI; Anzueto A; Niederman MS; Agustí C JAMA; 2015 Feb; 313(7):677-86. PubMed ID: 25688779 [TBL] [Abstract][Full Text] [Related]
13. Hydrocortisone in Severe Community-Acquired Pneumonia. Dequin PF; Meziani F; Quenot JP; Kamel T; Ricard JD; Badie J; Reignier J; Heming N; Plantefève G; Souweine B; Voiriot G; Colin G; Frat JP; Mira JP; Barbarot N; François B; Louis G; Gibot S; Guitton C; Giacardi C; Hraiech S; Vimeux S; L'Her E; Faure H; Herbrecht JE; Bouisse C; Joret A; Terzi N; Gacouin A; Quentin C; Jourdain M; Leclerc M; Coffre C; Bourgoin H; Lengellé C; Caille-Fénérol C; Giraudeau B; Le Gouge A; N Engl J Med; 2023 May; 388(21):1931-1941. PubMed ID: 36942789 [TBL] [Abstract][Full Text] [Related]
14. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. A randomized controlled study. Marik P; Kraus P; Sribante J; Havlik I; Lipman J; Johnson DW Chest; 1993 Aug; 104(2):389-92. PubMed ID: 8339624 [TBL] [Abstract][Full Text] [Related]
15. Severe sepsis in community-acquired pneumonia: when does it happen, and do systemic inflammatory response syndrome criteria help predict course? Dremsizov T; Clermont G; Kellum JA; Kalassian KG; Fine MJ; Angus DC Chest; 2006 Apr; 129(4):968-78. PubMed ID: 16608946 [TBL] [Abstract][Full Text] [Related]
16. Factors Associated With Treatment Failure in Moderately Severe Community-Acquired Pneumonia: A Secondary Analysis of a Randomized Clinical Trial. Dinh A; Duran C; Ropers J; Bouchand F; Davido B; Deconinck L; Matt M; Senard O; Lagrange A; Mellon G; Calin R; Makhloufi S; de Lastours V; Mathieu E; Kahn JE; Rouveix E; Grenet J; Dumoulin J; Chinet T; Pépin M; Delcey V; Diamantis S; Benhamou D; Vitrat V; Dombret MC; Guillemot D; Renaud B; Claessens YE; Labarère J; Aegerter P; Bedos JP; Crémieux AC; JAMA Netw Open; 2021 Oct; 4(10):e2129566. PubMed ID: 34652445 [TBL] [Abstract][Full Text] [Related]
17. Clinical effects of bacteremia in sepsis patients with community-acquired pneumonia. Kim TW; Lee SU; Park B; Jeon K; Park S; Suh GY; Oh DK; Lee SY; Park MH; Lee H; Lim CM; Ko RE; BMC Infect Dis; 2023 Dec; 23(1):887. PubMed ID: 38114902 [TBL] [Abstract][Full Text] [Related]
18. Corticosteroid treatment of severe community-acquired pneumonia. Gorman SK; Slavik RS; Marin J Ann Pharmacother; 2007 Jul; 41(7):1233-7. PubMed ID: 17519300 [TBL] [Abstract][Full Text] [Related]
19. Severe community-acquired pneumonia: current management and future therapeutic alternatives. Garnacho-Montero J; Barrero-García I; Gómez-Prieto MG; Martín-Loeches I Expert Rev Anti Infect Ther; 2018 Sep; 16(9):667-677. PubMed ID: 30118377 [TBL] [Abstract][Full Text] [Related]
20. [Change of prognosis and pathogens in adult patients with severe community-acquired pneumonia during different periods]. Zhang L; Ning P; Rong F; Gao ZC Zhonghua Yi Xue Za Zhi; 2017 Feb; 97(5):332-337. PubMed ID: 28219188 [No Abstract] [Full Text] [Related] [Next] [New Search]